Caladrius Bioscience To Start Testing Its CD34+ Cell Therapy in Diabetic Kidney Disease
The FDA has signed off Caladrius Bioscience Inc’s (NASDAQ:CLBS) investigational new drug application for the study of CLBS201 for the treatment…
Why Moderna, Bio-Path Holdings And vTv Therapeutics Are Moving Today
Moderna, Inc. (NASDAQ: MRNA), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and vTv Therapeutics Inc.
Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer
Corcept Therapeutics Incorporated (NASDAQ:CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer. The…
Lineage’s Spinal Cord Injury Cell Therapy Return To Clinical Testing
Following feedback received from the FDA, Lineage Cell Therapeutics Inc (NYSE:LCTX) will submit an amendment to its Investigational New Drug…
Innate Pharma’s Lacutamab Shows Clinical Responses In KIR3DL2-Expressing Mycosis Fungoides Patients
Innate Pharma SA (NASDAQ:IPHA) has announced preliminary data from the mycosis fungoides (MF) cohort of the Phase 2 TELLOMAK clinical trial,…
AstraZeneca’s Koselugo Gets European Nod To Treat Children With Multisystem Genetic Disorder
European Union has approved AstraZeneca plc’s (NASDAQ:AZN) Koselugo to treat children with neurofibromatosis type 1 and plexiform neurofibromas. Neurofibromatosis type…
Jupiter Wellness Highlights Publication Of Clinical Study Results Showing JW 100 ‘Significantly Reduces ISGA Score in Atopic Dermatitis’
https://pubmed.ncbi.nlm.nih.gov/34056830/
JUPITER, FL / ACCESSWIRE / June 22, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced the publication of clinical study results to investigate the
Corcept Therapeutics Stops Enrollment In RELIANT Trial; Says ‘the apparent level of benefit does not justify its further study as a treatment for end-stage pancreatic cancer’
Enrollment stopped in RELIANT trial
Antitumor activity observed in heavily pretreated patients with metastatic pancreatic cancer, including those previously treated with nab-paclitaxel; addition of relacorilant to
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy’s Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 21)
BioCardia To Present CardiAMP Cell Therapy Clinical Trial Data At European Society Of Cardiology Heart Failure 2021
BioCardia®, Inc. (NASDAQ:BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its